Sanofi Prepares for Regulatory Submission of Tolebrutinib in Non-Relapsing Secondary Progressive Multiple Sclerosis

Tolebrutinib, BTK inhibitor, Multiple sclerosis, Non-relapsing secondary progressive multiple sclerosis (nrSPMS), Sanofi, HERCULES study, GEMINI 1 and 2 studies, Regulatory approval

Cigna Challenges FTC’s Report on Pharmacy Benefit Managers, Alleging Unconstitutional Actions and Misleading Claims

Cigna, FTC, Pharmacy Benefit Managers (PBMs), Express Scripts, Unconstitutional Report, Misleading Claims, Drug Prices, Healthcare System